{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T17:03:01Z","timestamp":1791219781545,"version":"4.1.0"},"reference-count":61,"publisher":"Cambridge University Press (CUP)","issue":"9","license":[{"start":{"date-parts":[[2020,5,27]],"date-time":"2020-05-27T00:00:00Z","timestamp":1590537600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":["cambridge.org"],"crossmark-restriction":true},"short-container-title":["Infect. Control Hosp. Epidemiol."],"published-print":{"date-parts":[[2020,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Classical stewardship efforts have targeted immunocompetent patients; however, appropriate use of antimicrobials in the immunocompromised host has become a target of interest. Cytomegalovirus (CMV) infection is one of the most common and significant complications after solid-organ transplant (SOT). The treatment of CMV requires a dual approach of antiviral drug therapy and reduction of immunosuppression for optimal outcomes. This dual approach to CMV management increases complexity and requires individualization of therapy to balance antiviral efficacy with the risk of allograft rejection. In this review, we focus on the development and implementation of CMV stewardship initiatives, as a component of antimicrobial stewardship in the immunocompromised host, to optimize the management of prevention and treatment of CMV in SOT recipients. These initiatives have the potential not only to improve judicious use of antivirals and prevent resistance but also to improve patient and graft survival given the interconnection between CMV infection and allograft function.<\/jats:p>","DOI":"10.1017\/ice.2020.203","type":"journal-article","created":{"date-parts":[[2020,5,27]],"date-time":"2020-05-27T08:28:12Z","timestamp":1590568092000},"page":"1068-1074","update-policy":"https:\/\/doi.org\/10.1017\/policypage","source":"Crossref","is-referenced-by-count":31,"title":["The development and implementation of stewardship initiatives to optimize the prevention and treatment of cytomegalovirus infection in solid-organ transplant recipients"],"prefix":"10.1017","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6088-9727","authenticated-orcid":false,"given":"Margaret R.","family":"Jorgenson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jillian L.","family":"Descourouez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas T.","family":"Schulz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry A.","family":"Goldrosen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Rice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert R.","family":"Redfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher M.","family":"Saddler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeannina A.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier A.","family":"Mandelbrot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"56","published-online":{"date-parts":[[2020,5,27]]},"reference":[{"key":"S0899823X20002032_ref49","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis494"},{"key":"S0899823X20002032_ref45","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.13512"},{"key":"S0899823X20002032_ref44","unstructured":"44. Core elements of hospital antibiotic stewardship programs. Centers for Disease Control and Prevention website. https:\/\/www.cdc.gov\/antibiotic-use\/core-elements\/hospital.html. Accessed May 11, 2020."},{"key":"S0899823X20002032_ref41","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.13636"},{"key":"S0899823X20002032_ref39","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2004.00735.x"},{"key":"S0899823X20002032_ref35","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2010.03114.x"},{"key":"S0899823X20002032_ref31","doi-asserted-by":"publisher","DOI":"10.1097\/MOT.0000000000000666"},{"key":"S0899823X20002032_ref28","doi-asserted-by":"publisher","DOI":"10.1086\/342601"},{"key":"S0899823X20002032_ref19","article-title":"Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients","volume":"2","author":"Hodson","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"S0899823X20002032_ref46","doi-asserted-by":"publisher","DOI":"10.1111\/tid.12991"},{"key":"S0899823X20002032_ref16","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.10.2811-2815.2000"},{"key":"S0899823X20002032_ref15","doi-asserted-by":"publisher","DOI":"10.2217\/fvl.12.8"},{"key":"S0899823X20002032_ref10","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciq145"},{"key":"S0899823X20002032_ref11","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1111\/ajt.15183","article-title":"Cytomegalovirus mismatch still negatively affects patient and graft survival in the era of routine prophylactic and preemptive therapy: a paired kidney analysis","volume":"19","author":"Leeaphorn","year":"2019","journal-title":"Am J Transplant"},{"key":"S0899823X20002032_ref22","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciq145"},{"key":"S0899823X20002032_ref26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1706640"},{"key":"S0899823X20002032_ref40","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1097\/TP.0b013e31822fa4b7","article-title":"Clinical utility of molecular surveillance for cytomegalovirus after antiviral prophylaxis in high-risk solid organ transplant recipients","volume":"92","author":"Lisboa","year":"2011","journal-title":"Transplantation"},{"key":"S0899823X20002032_ref29","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2011.03766.x"},{"key":"S0899823X20002032_ref36","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e31821fad25"},{"key":"S0899823X20002032_ref55","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.15315"},{"key":"S0899823X20002032_ref60","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jix357"},{"key":"S0899823X20002032_ref23","doi-asserted-by":"crossref","first-page":"294","DOI":"10.2215\/CJN.07020714","article-title":"Randomized trial of valganciclovir versus valacyclovir prophylaxis for prevention of cytomegalovirus in renal transplantation","volume":"10","author":"Reischig","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"S0899823X20002032_ref17","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofx163.1967"},{"key":"S0899823X20002032_ref12","doi-asserted-by":"publisher","DOI":"10.1111\/tid.13189"},{"key":"S0899823X20002032_ref33","doi-asserted-by":"publisher","DOI":"10.1089\/sur.2015.266"},{"key":"S0899823X20002032_ref50","unstructured":"50. Fryer, JF HA , Anderson, R , Minor, PD , and the collaborative study group. Collaborative study to evaluate the proposed 1st WHO International Standard for human cytomegalovirus (HCMV) for nucleic acid amplification (NAT)-based assays. WHO ECBS Report 2010. World Health Organization website. www.who.int\/biologicals\/expert_committee\/TRS_978_61st_report.pdf?ua=1. Published 2010. Accessed May 12, 2020."},{"key":"S0899823X20002032_ref20","unstructured":"20. Valcyte prescribning information. Genentech website. https:\/\/www.gene.com\/download\/pdf\/valcyte_prescribing.pdf. Updated 2018. Accessed May 11, 2020."},{"key":"S0899823X20002032_ref51","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01287-11"},{"key":"S0899823X20002032_ref47","doi-asserted-by":"publisher","DOI":"10.1111\/tid.12849"},{"key":"S0899823X20002032_ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2018.01.023"},{"key":"S0899823X20002032_ref5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2010.03114.x"},{"key":"S0899823X20002032_ref38","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e318192ded5"},{"key":"S0899823X20002032_ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.idc.2014.01.008"},{"key":"S0899823X20002032_ref27","unstructured":"27. Letermovir versus valganciclovir to prevent human cytomegalovirus disease in kidney transplant recipients (MK-8228-002). ClinicalTrials.gov website. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03443869. Updated May 8, 2020. Accessed May 12, 2020."},{"key":"S0899823X20002032_ref7","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1987"},{"key":"S0899823X20002032_ref30","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2012.04087.x"},{"key":"S0899823X20002032_ref34","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1093\/ndt\/gfg251","article-title":"Efficacy and safety of lowering immunosuppression to treat CMV infection in renal transplant recipients on valaciclovir prophylaxis: a pilot study","volume":"18","author":"Anglicheau","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"S0899823X20002032_ref57","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000001095"},{"key":"S0899823X20002032_ref43","unstructured":"43. 2017 Annual Data Report. Scientific Registry of Transplant Recipients website. http:\/\/srtr.transplant.hrsa.gov\/annual_reports\/Default.aspx. Accessed October 22, 2019."},{"key":"S0899823X20002032_ref32","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00561-13"},{"key":"S0899823X20002032_ref18","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000002191"},{"key":"S0899823X20002032_ref58","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiz493"},{"key":"S0899823X20002032_ref2","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1086\/665010","article-title":"Policy statement on antimicrobial stewardship by the Society for Healthcare Epidemiology of America (SHEA), the Infectious Diseases Society of America (IDSA), and the Pediatric Infectious Diseases Society (PIDS)","volume":"33","year":"2012","journal-title":"Infect Control Hosp Epidemiol"},{"key":"S0899823X20002032_ref25","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2126"},{"key":"S0899823X20002032_ref13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra064928"},{"key":"S0899823X20002032_ref54","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0189488"},{"key":"S0899823X20002032_ref48","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-0012.2007.00761.x"},{"key":"S0899823X20002032_ref4","doi-asserted-by":"publisher","DOI":"10.1097\/QCO.0000000000000380"},{"key":"S0899823X20002032_ref8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2004.00382.x"},{"key":"S0899823X20002032_ref52","doi-asserted-by":"publisher","DOI":"10.1086\/654931"},{"key":"S0899823X20002032_ref14","doi-asserted-by":"publisher","DOI":"10.1038\/cmi.2014.75"},{"key":"S0899823X20002032_ref53","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00563-13"},{"key":"S0899823X20002032_ref56","doi-asserted-by":"publisher","DOI":"10.1111\/tri.13110"},{"key":"S0899823X20002032_ref59","unstructured":"59. Anderholm, KM , Bierle, CJ , Schleiss, MR. Cytomegalovirus vaccines: current status and future prospects drugs. 2016;76:1625\u20131645."},{"key":"S0899823X20002032_ref61","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy549"},{"key":"S0899823X20002032_ref37","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00317.2015"},{"key":"S0899823X20002032_ref6","doi-asserted-by":"publisher","DOI":"10.1111\/tid.12537"},{"key":"S0899823X20002032_ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajic.2006.05.237"},{"key":"S0899823X20002032_ref9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02597-6"},{"key":"S0899823X20002032_ref42","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-0012.2010.01208.x"},{"key":"S0899823X20002032_ref24","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1186\/s12879-018-3493-y","article-title":"Less renal allograft fibrosis with valganciclovir prophylaxis for cytomegalovirus compared to high-dose valacyclovir: a parallel group, open-label, randomized controlled trial","volume":"18","author":"Reischig","year":"2018","journal-title":"BMC Infect Dis"}],"container-title":["Infection Control &amp; Hospital Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0899823X20002032","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T14:52:37Z","timestamp":1696171957000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0899823X20002032\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,27]]},"references-count":61,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S0899823X20002032"],"URL":"https:\/\/doi.org\/10.1017\/ice.2020.203","relation":{},"ISSN":["0899-823X","1559-6834"],"issn-type":[{"value":"0899-823X","type":"print"},{"value":"1559-6834","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,27]]},"assertion":[{"value":"\u00a9 2020 by The Society for Healthcare Epidemiology of America. All rights reserved.","name":"copyright","label":"Copyright","group":{"name":"copyright_and_licensing","label":"Copyright and Licensing"}}]}}